Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REPRISE China: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Edge™ Valve System - Clinical Evaluation in China

NCT03084510 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT03084510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03084510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REPRISE China: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Edge™ Valve System - Clinical Evaluation in China
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Withdrawn
Start date
February 28, 2020
Completion date
November 30, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stenoses, aortic valve